NL-OMON25989CompletedNot Applicable
Methotrexate versus Expectant management in women with ectopic pregnancy.
Academic Medical Center, University of Amsterdam Obstetrics and Gynaecology (H4-205) Meibergdreef 9 1105 AZ AMSTERDAM THE NETHERLANDS tel: +31 20 5663693 fax: +31 20 69634890 sites72 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 72
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •All hemodynamically stable patients
- •> 18 years with either a suspected ectopic pregnancy (a visible ectopic pregnancy or an ectopic mass on Trans Vaginal Sonography) and a plateauing serum hCG concentration < 1,500 IU/L or with a Pregnancy of Unknown Location (PUL) and a plateauing serum hCG concentration < 2,000 IU/L (persisting PUL).
Exclusion Criteria
- •Patients with a viable ectopic pregnancy, signs of tubal rupture or active intra abdominal bleeding, abnormalities in liver or renal function or in full blood count.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Methotrexate versus expectant management in women with ectopic pregnancy (METEX study) - METEX studyEUCTR2006-003003-39-NLAcademic Medical Center72
Completed
Not Applicable
Methotrexate versus expectant management in women with ectopic pregnancyEctopic pregnancyISRCTN48210491Academic Medical Center (AMC) (The Netherlands)72
Not yet recruiting
Phase 4
The METEX Study: methotrexate versus expectant management in women with ectopic pregnancyEctopic PregnancyTubal PregnancyNL-OMON30421Academisch Medisch Centrum72
Recruiting
Not Applicable
Local vs Systemic Methotrexate in Management of Uterine Ectopic PregnancyLocalSystemicMethotrexateUterine Ectopic PregnancyNCT06554470Tanta University34
Not yet recruiting
Unknown
Comparing methotrexate and methotrexate with methotrexate with apremilast in modifying biochemical parameters of psoriasis patients.CTRI/2023/03/050882Anisha Biswal